Single versus combination intravenous antibiotic therapy for people with cystic fibrosis

beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

“…Information regarding colonisation was scarce. In a recent review that compared single versus combination therapy for patients with cystic fibrosis, monotherapy was associated with an increased risk of carriage of resistant P aeruginosa at follow up, but duration of treatment was longer 9. As we could assess only superinfections, we can conclude that for the individual patient, during a specific episodes of infection, differences in development of resistance are clinically non-significant.…”

“…We assessed heterogeneity with χ 2 test. As we anticipated heterogeneity between studies comparing the same β lactam and studies comparing different β lactams9 we separated analysis of these trials. The effect of measures of quality was examined through sensitivity analysis.…”

British Thoracic Society guideline for non-CFbronchiectasis

“…A meta-analysis of single versus combination antibiotic therapy in CF did not show differences in response but was associated with an increase in the number of patients with resistant P aeruginosa at 2–8 weeks in patients on monotherapy 437. A consensus statement concluded that, with a susceptible strain, monotherapy may be as effective as combination treatment.…”

Systematic reviews and lifelong diseases

“…We carried out a systematic review to assess the effectiveness of single compared with combination intravenous antibiotic therapy to treat respiratory exacerbations in people with cystic fibrosis 3. Here we focus on the comparison of a β lactam antibiotic with a β lactam and aminoglycoside combination.…”